Mark Plavsic
Chief Tech/Sci/R&D Officer en AURA BIOSCIENCES, INC. .
Fortuna: 2 M $ al 31/03/2024
Perfil
El Dr. Mark Plavsic es Director Técnico de Fate Therapeutics, Inc. El Dr. Plavsic trabajó anteriormente como Director Técnico en Lysogene SA y como Jefe de Desarrollo de Procesos y Fabricación en Torque Therapeutics, Inc. Se licenció en la Universidad de Belgrado y se doctoró en la Universidad de Belgrado.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0.26% | 15/03/2024 | 128 515 ( 0.26% ) | 1 M $ | 31/03/2024 |
FATE THERAPEUTICS, INC.
0.12% | 10/01/2023 | 123 705 ( 0.12% ) | 907 995 $ | 31/03/2024 |
Cargos activos de Mark Plavsic
| Empresas | Cargo | Inicio |
|---|---|---|
| AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 02/10/2023 |
TeraPore Technologies, Inc.
 TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Director/Board Member | - |
Antiguos cargos conocidos de Mark Plavsic.
| Empresas | Cargo | Fin |
|---|---|---|
| FATE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 06/03/2023 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| LYSOGENE | Chief Tech/Sci/R&D Officer | - |
Formación de Mark Plavsic.
| University of Belgrade | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| LYSOGENE | Commercial Services |
| Empresas privadas | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
TeraPore Technologies, Inc.
TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Process Industries |
- Bolsa de valores
- Insiders
- Mark Plavsic
